Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients ≥ 18 years of age with CRH, defined as those who require a total sum catecholamine dose of \> 0.2 mcg/kg/min for a minimum of 6 hours and a maximum of 48 hours, to maintain a MAP between 55-70 mmHg.~2. Patients are required to have central venous access and an arterial line present, and these are expected to remain present for at least the initial 48 hours of study.~3. Patients are required to have an indwelling urinary catheter present, and it is expected to remain present for at least the initial 48 hours of study.~4. Patients must have received at least 25 mL/kg of crystalloid or colloid equivalent over the previous 24-hour period, and be adequately volume resuscitated in the opinion of the treating investigator.~5. Patients must have clinical features of high-output shock by meeting one of the following criteria.~   1. Central venous oxygen saturation (ScvO2) \> 70% (either by oximetry catheter or by central venous blood gas) and central venous pressure (CVP) \> 8 mmHg.~      OR~  2. Cardiac Index (CI) \> 2.3 L/min/1.73 m2. Patient must meet 5a or 5b to be eligible.~6. Patient or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements.~Exclusion Criteria:~1. Patients who are \< 18 years of age.~2. Any patient with burns covering \> 20% of total body surface area (TBSA).~3. Patients with a Cardiovascular (CV) SOFA score ≤ 3.~4. Patients diagnosed with acute occlusive coronary syndrome requiring intervention.~5. Patients on veno-arterial (VA) ECMO.~6. Patients who have been on ECMO for less than 12 hours.~7. Patients in liver failure with a Model for End-Stage Liver Disease (MELD) score of ≥ 30.~8. Patients with a history of asthma or who are currently experiencing bronchospasm requiring the use of inhaled bronchodilators, if not mechanically ventilated.~9. Patients with acute mesenteric ischemia or a history of mesenteric ischemic.~10. Patients with a history of, presence of, or highly-suspected of having an aortic dissection or abdominal aortic aneurysm.~11. Patients requiring more than 500 mg daily of hydrocortisone or equivalent glucocorticoid medication as a standing dose.~12. Patients with Raynaud's phenomenon, systemic sclerosis or vasospastic disease.~13. Patients with an expected lifespan of \< 12 hours.~14. Patients with active bleeding AND an anticipated need (within 48 hours of initiation of the study) for transfusion of \> 4 units of packed red blood cells.~15. Patients with active bleeding AND hemoglobin \< 7g/dL or any other condition that would contraindicate serial blood sampling.~16. Patients with an absolute neutrophil count (ANC) of \< 1000 cells/mm3.~17. Patients with a known allergy to mannitol.~18. Patients who are current participating in another interventional clinical trial.~19. Patients who are known to be pregnant at the time of Screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LJPC-501 (angiotensin II) (Type: EXPERIMENTAL): Treatment arm
- Placebo (0.9% sodium chloride solution) (Type: PLACEBO_COMPARATOR): Placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).